Takeda, a global biopharmaceutical leader, inaugurated its innovation capability centre (ICC) in Bengaluru on Wednesday, marking its first such facility in Asia. The centre is part of Takeda’s global digital transformation efforts to develop advanced solutions and enhance its operations worldwide.
The ICC aims to harness digital technologies like AI to accelerate research and development and improve healthcare outcomes. “The launch of our Bengaluru ICC is a pivotal moment in Takeda’s digital transformation journey,” said chief data and technology officer Gabriele Ricci.
“Tapping into local talent is vital in our quest to create better health for people and a brighter future for the communities we serve,” he added.
The Bengaluru ICC will focus on using AI to enhance healthcare efficiency and predictive analytics, developing innovative devices and solutions tailored to patient’s needs. It will leverage data science to enable informed decision-making for improved patient care.
The ICC in Bengaluru is Takeda’s third such centre, complementing existing hubs in Mexico and Slovakia. It is designed to foster innovation, improve operational efficiency, and accelerate the development of life-transforming therapies.
“The Bengaluru site is our flagship ICC, forming part of a network that is the digital heart of Takeda,” said Sanjay Patel, global head of innovation capability solutions and services.”
This centre is expected to generate jobs in India and strengthen Takeda’s global mission to deliver life-changing treatments to patients. “India was a natural choice for Takeda’s first ICC in Asia,” said Tilak Banerjee, head of Takeda ICC India.
The ICC will employ 750 professionals by the end of the year with expertise in software engineering, data analysis, and AI. It will also play a pivotal role in supporting the company’s broader global operations, including research and development, manufacturing, and plasma donor systems.
The solutions developed here will benefit patients, healthcare providers, and employees worldwide.
Founded in 1781 in Osaka, Japan, Takeda has grown into a global biopharmaceutical giant operating in about 80 countries, including India, for over 13 years. The company’s portfolio covers areas such as gastrointestinal disorders, rare diseases, immunology, oncology, and vaccines.